405 abstracts found.



Results filter

Image quantification: Do numbers help treatment stratification?

Year:

Session type:

Alan Jackson1
1University of Manchester

Therapeutic targeting of childhood medulloblastoma: strategies for blocking recurrence

Year:

Session type:

Sheila Singh1
1McMaster University

Integrating stem and progenitor cell contribution to intestinal self renewal

Year:

Session type:

Douglas Winton1
1Cancer Research UK Cambridge Institute

Genome-epigenome interplay in medulloblastoma

Year:

Session type:

Paul Northcott1
1St. Jude Children's Research Hospital

Translocations and catastrophe – chromothriptic disruption of transcription factors in ependymoma

Year:

Session type:

Richard Gilbertson1
1Cancer Research UK Cambridge Institute

Comprehensive analysis of cell-free tumour DNA in plasma and urine tracks disease burden and reveals clonal evolution in muscle invasive bladder cancer

Year:

Session type:

Christopher Smith1,Kristan van der Vos2,Keval Patel1,Charles Massie1,Francesco Marass1,James Morris1,Dana Tsui1,Florent Mouliere1,Vincent Gnanapragasam1,Tim Forshew3,Bas van Rhijn2,Nitzan Rosenfeld1,Michiel van der Heijden2
1University of Cambridge,2Netherlands Cancer Institute,3University College London

Molecular Profiling of Circulating Tumour Cells (CTCs) in Non-small cell lung cancer within the TRACERx study of Intratumoural Heterogeneity and Evolution

Year:

Session type:

Sakshi Gulati1,Francesca Chemi2,Dominic G Rothwell2,Deborah Burt2,Barbara Mesquita2,Christopher Wirth2,Gareth Wilson3,Jackie Pierce2,Ged Brady2,Charles Swanton4,Caroline Dive5
1Postdoctoral Scientist,2Cancer Research UK Manchester Institute,3The Francis Crick Institute,London, UK,4The Francis Crick Institute,London, UK and and on behalf of TRACERx consortium and Cancer Research UK Manchester/UCL Lung Cancer Centre of Excellence,5Cancer Research UK Manchester Institute and on behalf of TRACERx consortium and Cancer Research UK Manchester/UCL Lung Cancer Centre of Excellence

F-18 labelled 3’-deoxy-3’-fluorothymidine (FLT) positron emission tomography (PET) imaging in patients with advanced pancreatic ductal adenocarcinoma: proof-of-concept reproducibility sub-analysis.

Year:

Session type:

Angela Lamarca1,Prakash Manoharan2,Marie-Claude Asselin3,Peter J Julyan4,Mahbubunnabi Tamal3,Ioannis Trigonis3,Mairéad G McNamara5,Richard A Hubner1,Zarni Win6,Juan W Valle5,Azeem Saleem7
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom,2Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom,3University of Manchester Wolfson Molecular Imaging Centre (WMIC), Institute of Population Health, Manchester, United Kingdom,4Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom,5Department of Medical Oncology, The Christie NHS Foundation Trust; Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom,6Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom,7Department of Applications, Imanova Centre for Imaging Sciences, London, United Kingdom

THE PROMIS STUDY: DIAGNOSTIC ACCURACY OF MRI AND TRUS BIOPSY IN PROSTATE CANCER

Year:

Session type:

Louise Brown1,Hashim Ahmed2,Ahmed El-Shater Bosaily2,Gabe Rhian3,Kaplan Richard1,Yolanda Collaco-Moraes1,Katie Ward1,Richard Hindley4,Alex Freeman5,Alex Kirkham5,Robert Oldroyd6,Chris Parker7,Mark Emberton2,The PROMIS Study Group8
1MRC Clinical Trials Unit at UCL,2University College London,3University of York,4Hampshire Hospitals NHS Foundation Trust,5University College London Hospital NHS Foundation Trust,6Patient and Public Representative,7Royal Marsden Hospital,8PROMIS Collaborators

Plasma DNA for early cancer screening

Year:

Session type:

Yuk Ming Dennis Lo1
1The Chinese University of Hong Kong

Prostate cancer screening as national programme: Benefits at less harm and less cost

Year:

Session type:

Harry J. de Koning1
1Erasmus Medical Center, Rotterdam

Precision early diagnosis for oesophageal cancer

Year:

Session type:

Rebecca Fitzgerald1
1MRC Cancer Cell Unit, University of Cambridge

Inhibiting HOX-PBX binding in paediatric glioblastoma as a novel therapeutic treatment

Year:

Session type:

William Rogers1,Richard Morgan2,Hardev Pandha1
1University of Surrey,2University of Bradford

Deep sequencing of circulating tumour DNA for personalised cancer detection and monitoring

Year:

Session type:

Maximilian Diehn1
1Stanford University

The versatility of CTCs as a liquid biopsy: Biomarkers, biology and drug development

Year:

Session type:

Caroline Dive1
1Cancer Research UK Manchester Institute

Using circulating tumour DNA to improve the management of metastatic castration-resistant prostate cancer

Year:

Session type:

Gerhardt Attard1
1The Institute of Cancer Research

The contribution of genomic instability to malignant growth in Drosophila

Year:

Session type:

Cayetano Gonzalez1
1IRB-Barcelona and BIST

Aneuploidy as the large adaptive mutation: Mechanism and theory

Year:

Session type:

Rong Li1
1Johns Hopkins University School of Medicine

Rhabdovirus based oncolytic virus vaccines

Year:

Session type:

John Bell1
1Ottawa Hospital Research Institute

Systemic delivery of Enadenotucirev, a Group B oncolytic Adenovirus for the treatment of cancer

Year:

Session type:

Kerry Fisher1
1University of Oxford

How should we combine oncolytic virotherapy with other agents?

Year:

Session type:

Kevin Harrington1
1The Institute of Cancer Research

HPV drives tumor development throughout the head and neck: Improved prognosis is associated with an immune response largely restricted to the oropharynx

Year:

Session type:

Tim Fenton1,Ankur Chakravarthy1,Stephen Henderson1,Stephen Thirdborough2,Christian Ottensmeier2,Xiaoping Su3,Andrew Feber1,Matt Lechner1,Gareth Thomas2
1University College London,2University of Southampton,3MD Anderson Cancer Center, University of Texas

Targeting the androgen receptor in prostate cancer: A resilient foe

Year:

Session type:

Peter Nelson1
1Fred Hutchinson Cancer Research Center

Targeting tumour-infiltrating myeloid cells for prostate cancer therapy

Year:

Session type:

Andrea Alimonti1
1Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI)

Molecularly stratified therapeutic strategies for lethal prostate cancer

Year:

Session type:

Johann de Bono1
1The Institute of Cancer Research

Drug discovery and development to overcome cancer evolution and drug resistance

Year:

Session type:

Paul Workman1
1The Institute of Cancer Research

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

Year:

Session type:

Nnenna Kanu1
1UCL Cancer Institute

Mutational signatures and cancer evolution

Year:

Session type:

Serena Nik-Zainal1
1Wellcome Trust Sanger Institute

Loss of primary cilia and tissue hyperplasia associated with centrosome amplification

Year:

Session type:

David Glover1
1University of Cambridge

Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer?

Year:

Session type:

Andreas Strasser1
1The Walter and Eliza Hall Institute

Identifying human cancers to target with BCL-2 inhibition

Year:

Session type:

Anthony Letai1
1Dana-Farber Cancer Institute

Harnessing the complex relationship between mitosis and cell death

Year:

Session type:

Pascal Meier1
1The Institute of Cancer Research

Cell fate imbalance in the Oesophageal Epithelium: mutant cell competition

Year:

Session type:

Maria Alcolea1
1Wellcome Trust-MRC Cambridge Stem Cell Institute

Targeting flap endonuclease 1 (FEN1) for personalization of ovarian cancer therapy

Year:

Session type:

Reem Ali1,Dorjbal Dorjsuren2,David Maloney2,Ajit Jadhav2,Anton Simeonov2,David Wilson III3,Anna Grabowska1,Emad Rakha1,Srinivasan Madhusudan1
1Division of Cancer & Stem Cells, School of Medicine, University of Nottingham, UK,2NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA,3Laboratory of Molecular Gerontology, Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224-6825, USA

Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: results of a phase 0 clinical trial

Year:

Session type:

Simon Lord1,Dan Liu1,Wei-Chen Cheng1,Syed Haider1,Edoardo Gaude2,Eugene Teoh1,Neel Patel1,Tom Metcalf3,Daniel McGowan1,Ioannis Roxanis1,Zhang Qifeng4,Pankaj Roy5,Fergus Gleeson1,Alastair Thompson6,Michael Pollak7,Michael Wakelam4,Francesca Buffa1,Christian Frezza2,John Fenwick3,Adrian Harris1
1University of Oxford,2University of Cambridge,3University of Liverpool,4Babraham Institute,5Oxford University Hospitals NHS Foundation Trust,6MD Andersen Cancer Centre,7McGill University

Cancer stigma among ethnic minority women

Year:

Session type:

Laura Marlow1,Charlotte Vrinten1,Jo Waller1
1UCL

PARP trapping enhances oncolytic Reovirus cell killing in melanoma

Year:

Session type:

Joan Kyula-Currie1,Victoria Roulstone2,Richard Elliot3,Stephen Pettitt3,Dragomir Krastev3,Holly Barker3,Martin McLaughlin3,Chris Lord3,Alan Melcher3,Kevin Harrington3
1Instiitute of Cancer Research,2Institute of Cancer Research,3Institute of cancer research

Updated results from a phase 3 trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced melanoma (CheckMate 067)

Year:

Session type:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean-Jacques Grob5,C. Lance Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Dana Walker16,Joel Jiang16,Christine Horak16,James Larkin17,F. Stephen Hodi18
1Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College,2Oncology Institute of Veneto IRCCS,3University of Colorado Cancer Center,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology,5Hospital de la Timone,6Texas Oncology-Baylor Charles A. Sammons Cancer Center,7University of Michigan,8Department of Dermatology, University of Essen,9European Institute of Oncology,10Cross Cancer Institute,11Universitäts Spital,12Tasman Oncology Research,13Netherlands Cancer Institute,14University Hospital of Siena,15Peter MacCallum Cancer Centre,16Bristol-Myers Squibb,17Royal Marsden Hospital,18Dana-Farber Cancer Institute

The molecular epidemiology of rare and compound EGFR mutations in 14,304 non-small cell lung carcinomas

Year:

Session type:

Matthew Evans1,Brendan O'Sullivan1,Frances Hughes1,Claire Swift1,Reena Dessi1,Tina Mullis1,Matthew Smith1,Philippe Taniere1
1Queen Elizabeth Hospital Birmingham

Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy

Year:

Session type:

Philip Dunne1,Darragh McArt2,Paul O'Reilly2,Helen Coleman2,Maurice Loughrey2,Wendy Allen2,Simon McDade2,Sandra van Scaheybroeck2,Manuel Salto-Tellez2,Daniel Longley2,Mark Lawler2,Patrick Johnston2
1CCRCB Queen's University Belfast,2QUB

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing

Year:

Session type:

Jonas Demeulemeester1,Parveen Kumar2,Elen K. Møller3,Silje Nord3,David C. Wedge4,April Peterson5,Randi R. Mathiesen6,Renathe Fjelldal7,Masoud Zamani Esteki8,A. Jason Grundstad9,Elin Borgen7,Lars O. Baumbusch10,Anne-Lise Børresen-Dale3,Kevin P. White9,Bjørn Naume11,Vessela N. Kristensen3,Peter Van Loo1,Thierry Voet2
1The Francis Crick Institute, London, UK / Human Genome Laboratory, Department of Human Genetics, University of Leuven, Leuven, Belgium,2Laboratory of Reproductive Genomics, Department of Human Genetics, University of Leuven, Leuven, Belgium / Single-cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton, UK,3Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway,4Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK,5Institute for Genomics & Systems Biology and Department of Human Genetics, University of Chicago, Chicago, Illinois, USA / (Present address) Laboratory of Genetics, University of Wisconsin, Madison, Wisconsin, USA,6Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / (Present address) Department of Oncology, Akershus University Hospital, Lørenskog, Norway,7Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway,8Laboratory of Reproductive Genomics, Department of Human Genetics, University of Leuven, Leuven, Belgium,9Institute for Genomics & Systems Biology and Department of Human Genetics, University of Chicago, Chicago, Illinois, USA,10Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / (Present address) Department of Pediatric Research, Women and Children's Division, Oslo University Hospital, Rikshospitalet, Oslo, Norway,11K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway / Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Ten year trends of participation of teenagers and young adults (TYA) in selected NIHR National Cancer Research Network trials

Year:

Session type:

Lorna Fern1,Seema Alexander1,Jeremy Whelan2
1National Cancer Research Institute,2University College London Hospitals NHS Foundation Trust

A Hypoxia Transcriptomic Signature Predicting Benefit from Hypoxia-modifying Treatment for High Risk Bladder Cancer Patients

Year:

Session type:

Lingjian Yang1,Amanda Williamson1,Joely Irlam1,Helen Denley2,Peter Hoskin3,Ananya Choudhury1,Catharine West1
1University of Manchester,2Manchester Royal Infirmary,3Mount Vernon Hospital

Why don’t drug companies provide access to drug for use in combination with RT?

Year:

Session type:

Anthony Chalmers1
1Glasgow Centre for Cancer Research

PET-PANC: Multi-centre trial of 18Fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.

Year:

Session type:

Paula Ghaneh1,Wai-Lup Wong2,Sobhan Vinjamuri3,Colin Johnson4,Mohamed Abu Hilal5,Antony Higginson6,Andrew Smith7,Andrew Scarsbrook8,Colin Mckay9,Robert Sutcliffe10,Hemant Kocher11,David Cunningham12,Stephen Pereira13,Brian Davidson14,David Chang15,Saboor Khan16,Bal Sanghera17,Andrew Titman18,Gillian Lancaster19,Catrin Plumpton20,Seow Tien Yeo21,Robert Hanson22,Christopher Halloran23,John Neoptolemos23
1University of Liverpool,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Royal Liverpool and Broadgreen University Hospitals NHS Trust,4Faculty of Medicine, University of Southampton, Southampton, UK.,5Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,6Department of Radiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.,7Department of Gastrointestinal Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,8Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,9Department of Surgery, Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow, UK.,10Department of Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.,11Barts Cancer Institute, Barts and the London, London, UK.,12Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, UK.,13Institute for Liver and Digestive Health, University College London Hospitals NHS Foundation Trust, London, UK.,14Department of Surgery, Royal Free London NHS Foundation Trust, London, UK.,15Department of Surgery, Royal Blackburn Hospital- East Lancashire Hospitals NHS Trust, Blackburn,UK.,16Department of Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.,17Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK.,18Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK,19Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK.,20Centre for Health Economics and Medicines Evaluation, Bangor University, Lancaster, UK.,21Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.,22Liverpool Cancer Research UK Cancer Trials Unit, University of Liverpool, Liverpool, UK,23Department Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

Understanding different types of cervical screening non-participant: a population-based survey

Year:

Session type:

Jo Waller1,Jessica Haddrell2,Amanda Chorley2,Rebecca Ferrer3,Laura Marlow2
1University College London,2UCL,3NCI

Keeping the Customer Satisfied? #5 – Who’s Talking? Findings On Research Conversations From The National (English) Cancer Patient Experience Survey 2015

Year:

Session type:

Richard Stephens1,Matthew Baker2,Carolyn Morris2
1NCRI,2NCRI Consumer Forum

‘Searching for the new normal’: Exploring the role of language and metaphor in becoming a cancer survivor

Year:

Session type:

Lynda Appleton1
1Clatterbridge Cancer Centre

Enhancing responses to melanoma therapy with novel combinations of targeted therapy and immune checkpoint blockade

Year:

Session type:

Robert Szczepaniak Sloane1,Alexandre Reuben2,Ningping Feng2,Sarah Johnson2,Jill Garvey2,Jiong Chen2,Courtney Hudgens2,Luigi Nezi2,Teresa Manzo2,Mariana Pettaccia De Macedo2,John Miller2,Jianhua Hu2,Richard Davis2,Hong Jiang2,Peter Prieto2,Timothy Heffernan2,Elizabeth Burton2,Patrick Hwu2,Hussein Tawbi2,Alexander Lazar2,Michael T. Tetzlaff2,Joe Marszalek2,Willem Overwijk2,Zachary Cooper2,Michael A. Davies2,Jennifer A. Wargo2
1UT MD Anderson Cancer Center,2MD Anderson

Enhancing patient-centred care: Assessment and management of patients’ unmet needs

Year:

Session type:

Afaf Girgis1
1University of New South Wales